Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.
about
Ustekinumab in Crohn's disease: evidence to date and place in therapyLong-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.Biologic safety in psoriasis: review of long-term safety data.Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.Risk of cardiovascular disorders in psoriasis patients: current and future.Ustekinumab: differential use in psoriasisThe Th17 axis in psoriatic disease: pathogenetic and therapeutic implications.Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.Chronic, not acute, skin-specific inflammation promotes thrombosis in psoriasis murine modelsThe safety of systemic treatments that can be used for geriatric psoriasis patients: a reviewA Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to dateNo Significant Reduction of Circulating Endothelial-Derived and Platelet-Derived Microparticles in Patients with Psoriasis Successfully Treated with Anti-IL12/23Current and potential immune therapies and vaccines in the management of psoriasis.Psoriasis comorbidities: complications and benefits of immunobiological treatmentA tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis.Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.The concept of psoriasis as a systemic inflammation: implications for disease management.Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?Cardiovascular aspects of psoriasis: an updated review.Control of inflammatory heart disease by CD4+ T cells.Rational for statin use in psoriatic patients.Treatment of psoriasis and psoriatic arthritis.Phototherapy, psoriasis, and the age of biologics.Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis.Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.Myocardial infarction in a patient treated with anti-interleukin-12 biological agent for chronic plaque psoriasis.A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.The safety of ustekinumab for the treatment of psoriatic arthritis.Immunotargeting in the management of psoriasis.Hit hard and early: Can the march of psoriasis be halted?Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential.Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Ustekinumab for the treatment of psoriatic arthritis.Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.Spotlight on ustekinumab in moderate to severe plaque psoriasis.
P2860
Q28073787-84B9D5A5-332C-4F30-9931-880AEB694B00Q30574065-8B618D25-4CDC-4519-A4E5-261E087B06AEQ30577671-1BEC12DA-FBAB-44FF-A0CD-F6F8E6C4F167Q30904076-1C9BAB03-1A27-4A3C-B4CD-4904F33569C0Q34189897-F46008C0-5714-494F-8347-DF92C02F6F5FQ34323212-20775379-8AD3-40AA-8BCA-A9A11D1681ACQ35096980-0267D4CD-BCE6-40C8-B234-C6EF57314BF4Q35308947-44B0AB41-C9CF-4106-9C49-AFFD3D6504A2Q35606402-C2561907-35C5-49F8-9417-FECC9F8291AFQ35860158-B05FED6B-0B35-4F4A-A51D-19FDEC961524Q35870923-753CFE33-42E9-4FCB-9163-55C32E84ECC6Q36010949-F362BE11-FE13-4FB5-8F24-347B1A9E1E21Q36434758-7EB071D0-91EB-4386-9CA6-ABAFD2B5D555Q36643600-5E1B72CC-8ABE-4B65-B007-1ACD4D38E8BEQ36828238-5AEC75EA-E495-40EB-AA62-E4B20132D950Q36977772-245DA254-FEDF-472A-A57B-6CD196986942Q37540440-4D4844B5-8022-448E-8D88-84340097D15DQ37892623-0DFC8812-A104-4DF5-ABA9-CF6A8D3E2BDEQ37929165-0CA8E9DE-0E5F-4FFD-ADF1-D83B38461635Q37987268-A87ED3C8-0EAA-4CAC-A7EA-86842B6098A7Q38023581-E303E1CA-A380-4F86-B3CC-21BFBDF58B0EQ38076496-1CEE2F36-200E-432B-AA40-C97D4F024E04Q38108397-C1E0876D-671F-4840-B5EF-197A34499978Q38113531-9E7AAA91-122C-4F78-AF8B-86B59A4F56D4Q38132706-FAAA8CFE-7A77-42E3-B0C2-F22E00B733BBQ38169210-8079C75A-3657-4AA2-8182-C3C1DEC2CD00Q38231348-2F881A7A-E248-4B97-B158-F7116066BC0CQ38264660-C2E63AC6-1049-4CA4-990A-DA77A70A2A48Q38303098-DB30F15C-14F7-4644-815F-9F4054772383Q38749257-B7B80266-C6CF-470C-9310-F3CBBFB58942Q38820480-8191C0B9-1952-4275-9BE6-A2226DC81EF4Q38912240-73036427-CEB8-45E3-97A5-88774F8595EFQ41848576-F4313B27-603C-4811-A7D6-D56C0999BBDFQ42956548-87C92D57-8366-4AA4-BBC6-116B71B5BEFBQ46180528-5DC3E3EF-CCC6-49BC-8FEF-09C92E148145Q46338726-BD316BB0-23EF-458C-A850-B6A494EBE2AAQ47644680-15BC5A2B-4136-4DB4-A58E-E358AB352BE4Q48086737-B59AB6C7-C169-422E-A136-B4CA9BEBCABBQ48478885-F40D95AF-400B-4CA4-98DC-764AD52F9A2CQ48510956-2D8713C0-215B-4F0F-BC80-74C10445AD06
P2860
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cardiovascular safety of ustek ...... e II and III clinical studies.
@ast
Cardiovascular safety of ustek ...... e II and III clinical studies.
@en
type
label
Cardiovascular safety of ustek ...... e II and III clinical studies.
@ast
Cardiovascular safety of ustek ...... e II and III clinical studies.
@en
prefLabel
Cardiovascular safety of ustek ...... e II and III clinical studies.
@ast
Cardiovascular safety of ustek ...... e II and III clinical studies.
@en
P2093
P2860
P1476
Cardiovascular safety of ustek ...... se II and III clinical studies
@en
P2093
N Yeilding
R G Langley
P2860
P304
P356
10.1111/J.1365-2133.2011.10257.X
P407
P577
2011-04-01T00:00:00Z